VERACYTE, INC. — Director's Dealing 2019

Dec 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERACYTE, INC. (VCYT)
CIK: 0001384101
Period of Report: 2019-12-02

Reporting Person: Kennedy Giulia C (Chief Scientific & Med Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-02	Common Stock	F	292	$27.19	Disposed	47157	Direct
2019-12-03	Common Stock	M	3751	$6.45	Acquired	50908	Direct
2019-12-03	Common Stock	M	1563	$5.43	Acquired	52471	Direct
2019-12-03	Common Stock	M	5312	$9.05	Acquired	57783	Direct
2019-12-03	Common Stock	M	4406	$5.98	Acquired	62189	Direct
2019-12-03	Common Stock	S	15327	$26.4672	Disposed	46862	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-03	Stock Option (right to buy)	$6.45	M	3751	Disposed	2026-02-28	Common Stock (3751.0)	Direct
2019-12-03	Stock Option (right to buy)	$5.43	M	1563	Disposed	2026-03-14	Common Stock (1563.0)	Direct
2019-12-03	Stock Option (right to buy)	$9.05	M	5312	Disposed	2027-03-02	Common Stock (5312.0)	Direct
2019-12-03	Stock Option (right to buy)	$5.98	M	4406	Disposed	2028-03-01	Common Stock (4406.0)	Direct

Footnotes

F1: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person.

F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019.

F3: Represents weighted average sales price. Sale prices for the transactions range from $25.99 to $26.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

F4: The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F5: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F6: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F7: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.